Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Guardant Health (GH) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Guardant Health is a member of our Medical group, which includes 950 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Guardant Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for GH's full-year earnings has moved 3.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that GH has returned about 246.8% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 7% on a year-to-date basis. As we can see, Guardant Health is performing better than its sector in the calendar year.
Another stock in the Medical sector, Collegium Pharmaceutical (COLL), has outperformed the sector so far this year. The stock's year-to-date return is 67%.
Over the past three months, Collegium Pharmaceutical's consensus EPS estimate for the current year has increased 9.1%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Guardant Health belongs to the Medical - Biomedical and Genetics industry, a group that includes 467 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have gained 20% this year, meaning that GH is performing better in terms of year-to-date returns.
In contrast, Collegium Pharmaceutical falls under the Medical - Drugs industry. Currently, this industry has 147 stocks and is ranked #69. Since the beginning of the year, the industry has moved +7.7%.
Investors with an interest in Medical stocks should continue to track Guardant Health and Collegium Pharmaceutical. These stocks will be looking to continue their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Guardant Health, Inc. (GH): Free Stock Analysis Report Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
